港股公告掘金 | 百胜中国2025年总收入同比增长4%至118亿美元

智通财经03-02

【重大事项】九毛九(09922)拟合共斥资4300万美元收购北美连锁餐饮企业部分股权中国生物制药(01177)自主研发的国家1类创新药罗伐昔替尼片获批上市信达生物(01801)：捷帕力®(匹妥布替尼)在中国获批复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤适应症复宏汉霖(02696)：帕妥珠单抗生物类似药HLX11(重组抗HER2结构域II人源化单克隆抗体注射液)获欧洲药品管理局(EMA)人用...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2616081358?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-02 09:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616081358","market":"sh","top_or_hot":-1,"title":"港股公告掘金 | 百胜中国2025年总收入同比增长4%至118亿美元","media":"智通财经","content":"<div>\n<p>【重大事项】九毛九(09922)拟合共斥资4300万美元收购北美连锁餐饮企业部分股权中国生物制药(01177)自主研发的国家1类创新药罗伐昔替尼片获批上市信达生物(01801)：捷帕力®(匹妥布替尼)在中国获批复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤适应症复宏汉霖(02696)：帕妥珠单抗生物类似药HLX11(重组抗HER2结构域II人源化单克隆抗体注射液)获欧洲药品管理局(EMA)人用...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1408767.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股公告掘金 | 百胜中国2025年总收入同比增长4%至118亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股公告掘金 | 百胜中国2025年总收入同比增长4%至118亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-02 09:15 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1408767.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【重大事项】九毛九(09922)拟合共斥资4300万美元收购北美连锁餐饮企业部分股权中国生物制药(01177)自主研发的国家1类创新药罗伐昔替尼片获批上市信达生物(01801)：捷帕力®(匹妥布替尼)在中国获批复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤适应症复宏汉霖(02696)：帕妥珠单抗生物类似药HLX11(重组抗HER2结构域II人源化单克隆抗体注射液)获欧洲药品管理局(EMA)人用...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1408767.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0531971595.HKD","symbol_name":"HSBC GIF CHINESE EQUITY \"AD\" (HKD) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1408767.html","article_id":"2616081358","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616081358","pubTimestamp":1772414100,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【重大事项】九毛九(09922)拟合共斥资4300万美元收购北美连锁餐饮企业部分股权中国生物制药(01177)自主研发的国家1类创新药罗伐昔替尼片获批上市信达生物(01801)：捷帕力(匹妥布替尼)在中国获批复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤适应症复宏汉霖(02696)：帕妥珠单抗生物类似药HLX11(重组抗HER2结构域II人源化单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"81211":"比亚迪股份-R","LU0531971595.HKD":"HSBC GIF CHINESE EQUITY \"AD\" (HKD) INC","LU0871576103.HKD":"HSBC GIF CHINESE EQUITY \"AC\" (HKD) ACC","BK1588":"回港中概股","BK1610":"ETF&股票定投概念","YUMC":"百胜中国","LU2294711713.HKD":"BNP PARIBAS ENERGY TRANSITION \"C\" (HKD) ACC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0143863784.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES\"DU\" (USD) ACC","LU0823414478.USD":"法巴经典能源转换基金","SG9999006514.SGD":"United Asia Consumer Fund SGD","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","03969":"中国通号","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","BK4531":"中概回港概念","BK1233":"餐馆","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","VXUS":"国际股票ETF-Vanguard","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","BK1591":"就地过年概念","LU0269904917.USD":"SCHRODER ISF GLOBAL EMERGING MARKET OPPORTUNITIES \"A\" (USD) ACC","VT":"世界全股市ETF-Vanguard","09987":"百胜中国","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU0651946864.USD":"贝莱德新兴市场股票收益A2","LU0588545904.SGD":"Eastspring Investments - Asian Equity Income ASDM SGD","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","LU0588545730.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY INCOME \"ADM\" (USD) INC","IE0034224299.USD":"PINEBRIDGE ASIA EX JAPAN EQUITY \"A\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","HYDD.SI":"BYD HK SDR 10to1","LU0594300419.USD":"富达中国消费基金A","002594":"比亚迪","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1861219969.SGD":"Blackrock Future of Transport A2 SGD-H","LU0650527681.SGD":"Fidelity China Consumer A-SGD","BK1540":"电池","09922":"九毛九","LU0449509016.USD":"HSBC GIF BRIC EQUITY \"AC\" (USD) ACC","LU0214875030.USD":"HSBC GIF BRIC EQUITY \"M2C\" (USD) ACC","LU0254981946.USD":"HSBC GIF BRIC MARKETS EQUITY \"AC\" (USD) ACC","LU1515016050.SGD":"Blackrock Emerging Markets Equity Income A6 SGD-H","03931":"中创新航","BYDDY":"比亚迪ADR","LU2357125470.USD":"BNP PARIBAS ENERGY TRANSITION \"CLASSIC RH\" (USDHDG) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD"},"translate_title":"Hong Kong Stock Announcement Nuggets | Yum China's total revenue in 2025 will increase by 4% year-on-year to US $11.8 billion","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"81211":0.6,"09987":1.5,"VT":1.5,"03969":0.9,"09922":0.9,"HYDD.SI":0.6,"VXUS":1.5,"002594":0.6,"BYDDY":0.6,"YUMC":1.5,"03931":0.9},"content_text":"【重大事项】九毛九(09922)拟合共斥资4300万美元收购北美连锁餐饮企业部分股权中国生物制药(01177)自主研发的国家1类创新药罗伐昔替尼片获批上市信达生物(01801)：捷帕力®(匹妥布替尼)在中国获批复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤适应症复宏汉霖(02696)：帕妥珠单抗生物类似药HLX11(重组抗HER2结构域II人源化单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见复星国际(00656)拟回购不超过10亿港元的股份【财报数据】百胜中国(09987)发布年度业绩 总收入同比增长4%至118亿美元中国通号(03969)发布年度业绩快报 归母净利润36.61亿元 同比增长4.76%信义玻璃(00868)公布2025年业绩 股东应占溢利27.29亿元 同比减少19%澜起科技(06809)2025年度归母净利润22.36亿元 同比增加58.35%沃尔核材(09981)2025年归母净利约11.35亿元，同比增长33.95%信义能源(03868)发布年度业绩，股东应占溢利10.11亿元 同比增加27.79%信义光能(00968)公布2025年业绩 权益持有人应占溢利8.445亿元 同比减少16.2%中国光大水务(01857)发布年度业绩，股东应占盈利8.42亿港元 同比减少17% 末期息每股4.22港仙春立医疗(01858)2025年归母净利约2.72亿元，同比增长117.72%亿华通(02402)2025年归母净亏损约6.28亿元，同比增长37.65%纳芯微(02676)2025年归母净亏损约2.41亿元，同比收窄40.16%君实生物(01877)2025年归母净亏损约8.74亿元 同比收窄31.74%中创新航(03931)发盈喜 预期2025年度净利润约20.25亿元至21.93亿元 同比上升约140%至160%梦金园(02585)发盈警 预期2025年公司拥有人应占盈利同比减少约50%至59%碧桂园服务(06098)预期2025年实现综合收入约482亿-485亿元 同比增长9.6%至10.2%珍酒李渡(06979)发盈警 预期2025年股东应占利润约5.2亿元至5.8亿元 同比减少56.1%至60.6%奇瑞汽车(09973)2月五大品牌总销量为14.62万辆 同比减少约14.8%吉利汽车(00175)2月汽车总销量为20.62万部，同比增长约1%比亚迪股份(01211)2月新能源汽车销量约19.02万辆蔚来-SW(09866)2月交付20797辆汽车 同比增长57.6%长城汽车(02333)2月销量合计约72594台 同比减少6.79%理想汽车-W(02015)2月交付新车26421辆","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616081358","isCrawlerRequest":true}